Back to top
more

ShockWave Medical (SWAV)

(Delayed Data from NSDQ)

$330.38 USD

330.38
810,028

+0.38 (0.12%)

Updated May 3, 2024 04:00 PM ET

After-Market: $330.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Acadia (ACHC) Starts Construction of Malden's JV Facility

Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.

Shockwave Medical (SWAV) Up on Potential Acquisition Rumors

Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Humana (HUM) Inks Value-Based Deal to Offer Better Kidney Care

Humana (HUM) expands ties with Strive to offer high-quality kidney care to its Medicare Advantage members and thereby, aims to increase the customer base of the relevant business line.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

What Makes Shockwave Medical (SWAV) a Strong Momentum Stock: Buy Now?

Does Shockwave Medical (SWAV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

Smart Beta ETF report for GRPM

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

Style Box ETF report for GRPM

Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 26.09% and 1.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?

Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Shockwave Medical (SWAV) Down 1% Since Last Earnings Report: Can It Rebound?

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Implied Volatility Surging for ShockWave Medical (SWAV) Stock Options

Investors need to pay close attention to ShockWave Medical (SWAV) stock based on the movements in the options market lately.

Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 13.58% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.

Should You Buy ShockWave Medical (SWAV) Ahead of Earnings?

ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Shockwave Medical (SWAV) Crossed Above the 50-Day Moving Average: What That Means for Investors

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Lantheus (LNTH) to Report Q3 Earnings: What's in the Cards?

Lantheus' (LNTH) third-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Shockwave Medical (SWAV) Just Overtook the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Charles River (CRL) to Report Q3 Earnings: What's in Store?

Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

What's in Store for Cardinal Health (CAH) in Q1 Earnings?

Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.